CAPRCapricor Therapeutics, Inc.
$5.92-3.9% 1Y
$5.92
$3.8452 weeks$35.34
Is the business good?
Good
1 good, 3 without dataMargins widening. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Margin direction, 3 years+576.6 ptsderived
Operating margin has widened over the past few years, the business is getting more profitable per dollar of sales.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is CAPR?
- Share count, year on year
- +27%
Share count, year on year · shareholders own a smaller slice than a year ago
| Year | Operating margin |
|---|---|
| FY2020 | −4413% |
| FY2021 | −8550% |
| FY2022 | −1164% |
| FY2023 | −96% |
| FY2024 | −191% |
Details›
- Free cash flow, trailing twelve months
- −$115M
- Net income, trailing twelve months
- −$129M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
On our screens:Most shorted stocks